Cancer cells often exhibit chromosomal abnormalities, including chromosomal rearrangements (such as translocations), deletions, and duplications. These abnormalities can disrupt the normal function of genes involved in
cell cycle regulation, leading to uncontrolled cell growth and tumor formation. The
chromosome theory of cancer is a long-standing idea originated from the work of
Theodor Boveri, a German biologist, in the early 20th century. Boveri's studies on
sea urchin eggs provided early evidence that abnormal chromosome numbers could lead to developmental defects, leading him to propose a connection between
chromosomal abnormalities and cancer. Further research by scientists such as
David Hungerford and
Peter Nowell in the 1960s identified specific chromosomal abnormalities in
cancer cells, such as the
Philadelphia chromosome in
chronic myeloid leukemia, providing more support for the chromosomal theory of cancer. The
chromosomal theory of
cancer is a fundamental concept in
cancer biology that suggests cancer is caused by
genetic changes, particularly alterations in the structure or number of
chromosomes in
cells. These changes can lead to uncontrolled
cell growth, a hallmark of cancer. CIN is a more pervasive mechanism in cancer genetic instability than simple accumulation of point mutations. The degree of instability varies between cancer types. For example, in cancers where mismatch repair mechanisms are defective – like some colon and breast cancers – their chromosomes are relatively stable. The research associated with chromosomal instability is associated with solid tumors, which are tumors that refer to a solid mass of cancer cells that grow in organ systems and can occur anywhere in the body. These tumors are opposed to liquid tumors, which occur in the blood, bone marrow, and lymph nodes. Although chromosome instability has long been proposed to promote tumor progression, recent studies suggest that chromosome instability can either promote or suppress tumor progression. This is due to the fact that a large rate of chromosomal instability is detrimental to the survival mechanisms of the cell, Therefore, the relationship between chromosomal instability and cancer can also be used to assist with diagnosis of malignant vs. benign tumors. A majority of human solid malignant tumors is characterized by chromosomal instability, and have gain or loss of whole chromosomes or fractions of chromosomes. This shows that chromosomal instability can be responsible for the development of solid cancers. However, genetic alterations in a tumor do not necessarily indicate that the tumor is genetically unstable, as 'genomic instability' refers to various instability phenotypes, including the chromosome instability phenotype While some argue the canonical theory of
oncogene activation and
tumor suppressor gene inactivation, such as
Robert Weinberg, some have argued that CIN may play a major role in the origin of cancer cells, since CIN confers a mutator phenotype that enables a cell to accumulate large number of mutations at the same time. Scientists active in this debate include Christoph Lengauer, Kenneth W. Kinzler, Keith R. Loeb, Lawrence A. Loeb,
Bert Vogelstein and
Peter Duesberg. Current research in cancer genetics is focused on further understanding the role of
chromosomal abnormalities in cancer development and progression. Advances in technology, such as next-generation
sequencing, are enabling researchers to study chromosomal abnormalities in cancer cells with greater detail and precision.
Chromosome instability in anticancer therapy Hypothetically, the heterogeneous gene expression that can occur in a cell with CIN, the rapid genomic changes can drive the emergence of drug-resistant tumor cells. While some studies show that CIN is associated with poor patient outcomes and drug resistance, conversely, others studies actually find that people respond better with high CIN tumors. Some researchers believe that CIN can be stimulated and exploited to generate lethal interactions in tumor cells. ER negative breast cancer patients with the most extreme CIN have the best prognosis, with similar results for ovarian, gastric and non-small cell lung cancers. A potential therapeutic strategy therefore could be to exacerbate CIN specifically in tumor cells to induce cell death. For example,
BRCA1,
BRCA2 and BC-deficient cells have a sensitivity to
poly(ADP-ribose) polymerase (PARP) which helps repair single-stranded breaks. When PARP is inhibited, the replication fork can collapse. Therefore, PARP tumor suppressing drugs could selectively inhibit
BRCA tumors and cause catastrophic effects to breast cancer cells. Clinical trials of PARP inhibition are ongoing. There is still a worry that targeting CIN in therapy could trigger genome chaos that actually increases CIN that leads to selection of proliferative advantages. and
trastuzumab for
HER2-positive breast cancer, have been developed based on the specific chromosomal abnormalities associated with these cancers. == Chromosome instability and metastasis ==